{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:36:59Z","timestamp":1714610219357},"reference-count":14,"publisher":"ALUNA","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Aim: To study and investigate the incidence of Coronavirus infection in children, the course of the disease, the risks of complications and their interrelationships\nMaterials and Methods: Study included the analysis and observation of children (n=55, aged 14.36\u0081}3.62 years) with confirmed Coronerovirus infection, who were observed in the CNE \u226aCMCH\u226b in Uzhgorod in outpatient conditions. A study of clinical presentations, a clinical and laboratory examination followed by a mathematical analysis of the symptoms data in children with an identified Coronavirus infection and in the dynamics up to week 30 (with survey intervals in 3 weeks) from the diagnosis verification was carried out\nResults: A dynamic analysis of the clinical manifestation of symptoms in children with an identified Corona virus infection and within 30 weeks (with survey intervals of 3 weeks) from the beginning of the diagnosis verification was carried out. Complaints from the respiratory system were prevailed. The most long-lasting complaint was observed \u226achanges in the sense of taste and smell\u226b (from 35(63.6%) to 6(10.9%) up to 18 weeks inclusive. Other complaints \u226aCough, Rhinitis, Shortness of breath, Pain in the chest\u226b was observed for 6 weeks. Sore throat, muscular and joint pain were persisted for 3 weeks. Fever was not identified at week 3. Illness with other viral respiratory diseases started at week 9 and was observed until week 30 (from 10(18.2%) to 19(34.5%)) with varying levels. A decrease in cases of IgM identification was observed within 6 weeks (from 55, 100% to 20, 36, 4%). On the 9th week, the presence of IgM was not established. There is also an increase in the number of cases of detection of IgG in patients with a level maximum of 6 weeks.\nConclusions: There is a positive effect of the CRP level on the occurrence of symptoms of cough, rhinitis, shortness of breath, chest pain, change in taste and smell, muscle and joint pain (r=0.33-0.55), with the most significant data for the symptom of pain in chest (p=0.00001). Ferritin level interactions mostly had a negative direction (r=-0.35-0.48, p=0.02-0.00001) on the development of symptoms, with the exception of rhinorrhea (r=0.48, p=0.00002) and chest pains (r=0.39, 0.003). According to multiple logistic regression analysis the chance of the symptom of a change in taste and smell increases due to an increasing in the level of Procalcitonin in 1.48 times. The chance of the symptom of shortness of breath increased due to an increasing in the Ferritin level in 1.025 times<\/jats:p>","DOI":"10.36740\/wlek202403116","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T17:01:30Z","timestamp":1714582890000},"page":"484-490","source":"Crossref","is-referenced-by-count":0,"title":["Analysis and interpretation of Coronavirus infection children\u2019s incidence, contributing factors, risks of complications and their relationship"],"prefix":"10.36740","volume":"77","author":[{"given":"Olesya M.","family":"Horlenko","sequence":"first","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khrystyna","family":"Hechko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyubomyra B.","family":"Prylypko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mykhaylo","family":"Hechko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fedir V.","family":"Horlenko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian I.","family":"Tomey","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agneta V.","family":"Lenchenko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Leidman E, Duca LM, Omura JD et al. COVID-19 trends among persons aged 0-24 years - United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(3):88-94. doi: 10.15585\/mmwr.mm7003e1.","DOI":"10.15585\/mmwr.mm7003e1"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Antypkin YUH, Lapshyn VF, Umanets TR et al. Analiz poshyrenosti COVID-19 sered dytyachoho naselennya Ukrayiny v pershyy rik pandemiyi [Analysis of the prevalence of COVID-19 among children in Ukraine in the first year of the pandemic]. Zdorov\u2019ya dytyny. 2023;18(1):1-5. doi: 10.22141\/2224-0551.18.1.2023.1551. (Ukrainian)","DOI":"10.22141\/2224-0551.18.1.2023.1551"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Howard-Jones AR, Kok J. The SARS-CoV-2 Perfect storm: from humble betacoronavirus to global pandemic. Microbiology Australia. 2020;41(3):150-6. doi: 10.1071\/MA20040.","DOI":"10.1071\/ma20040"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Borrelli M, Corcione A, Castellano F et al. Coronavirus disease 2019 in children. Front Pediatr. 2021;9:668484. doi: 10.3389\/fped.2021.668484.","DOI":"10.3389\/fped.2021.668484"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Viner RM, Ward JL, Hudson LD et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch Dis Child. 2020. doi: 10.1136\/archdischild-2020-320972.","DOI":"10.1136\/archdischild-2020-320972"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6. Patel NA. Pediatric COVID-19: Systematic review of the literature. Am J Otolaryngol. 2020;41(5):102573. doi: 10.1016\/j.amjoto.2020.102573.","DOI":"10.1016\/j.amjoto.2020.102573"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. DeBiasi RL, Delaney M. Symptomatic and asymptomatic viral shedding in pediatric patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): under the surface. JAMA Pediatr. 2021;175(1):16-8. doi: 10.1001\/jamapediatrics.2020.3996.","DOI":"10.1001\/jamapediatrics.2020.3996"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8. Schober P, Vetter T. Logistic Regression in Medical Research. Anesth Analg. 2021;132(2):365-366. doi: 10.1213\/ANE.0000000000005247.","DOI":"10.1213\/ANE.0000000000005247"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Liu B, Jayasundara D, Pye V et al. Whole of population-based cohort study of recovery time from COVID-19 in New South Wales Australia. Lancet Reg Health West Pac. 2021;12:100193. doi: 10.1016\/j.lanwpc.2021.100193.","DOI":"10.1016\/j.lanwpc.2021.100193"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10. Kumar SS, Mirza T, Khatoon A et al. J Infect Public Health. 2023. doi: 10.1016\/j.jiph.2023.06.018.","DOI":"10.1016\/j.jiph.2023.06.018"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Williams PCM, Howard-Jones AR, Hsu P et al. SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings. Pathology. 2020;52(7):801-8. doi: 10.1016\/j.pathol.2020.08.001.","DOI":"10.1016\/j.pathol.2020.08.001"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12. Tosif S, Neeland MR, Sutton P et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nat Commun. 2020;11(1):5703. doi: 10.1038\/s41467-020-19545-8.","DOI":"10.1038\/s41467-020-19545-8"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Loske J, Rohmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. Nat Biotechnol. 2022;40(3):319-24. doi: 10.1038\/s41587-021-01037-9.","DOI":"10.1038\/s41587-021-01037-9"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Pierce CA, Sy S, Galen B et al. Natural mucosal barriers and COVID-19 in children. JCI Insight. 2021;6(9):e148694. doi: 10.1172\/jci. insight.148694.","DOI":"10.1172\/jci.insight.148694"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T17:08:57Z","timestamp":1714583337000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2024\/WiadLek2024i3.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202403116","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}